

Guy de Backer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3190120/publications.pdf>

Version: 2024-02-01

36
papers

19,624
citations

411340

20
h-index

425179

34
g-index

36
all docs

36
docs citations

36
times ranked

21672
citing authors

#	ARTICLE	IF	CITATIONS
1	A short history of the European Association of Preventive Cardiology (EAPC). <i>European Journal of Preventive Cardiology</i> , 2022, , .	0.8	1
2	Assessing the probability of risk factor control in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1465-1475.	0.8	9
3	Socioeconomic characteristics of patients with coronary heart disease in relation to their cardiovascular risk profile. <i>Heart</i> , 2021, 107, 799-806.	1.2	9
4	Smoking cessation in patients with established coronary artery disease: data from the POLASPIRE survey. <i>Kardiologia Polska</i> , 2021, 79, 418-425.	0.3	3
5	Dyslipidemia Management in Patients with Coronary Artery Disease. Data from the POLASPIRE Survey. <i>Journal of Clinical Medicine</i> , 2021, 10, 3711.	1.0	8
6	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2021, 42, 3227-3337.	1.0	2,517
7	INTERASPIRE: an International Survey of Coronary Patients; Their Cardiometabolic, Renal and Biomarker Status; and the Quality of Preventive Care Delivered in All WHO Regions. <i>Current Cardiology Reports</i> , 2021, 23, 136.	1.3	5
8	Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With Coronary Artery Disease—A Persistent Challenge in Need of Substantial Improvement: A Report From ESC EORP EUROASPIRE V. <i>Diabetes Care</i> , 2020, 43, 726-733.	4.3	46
9	Secondary prevention of coronary artery disease in Poland. Results from the POLASPIRE survey. <i>Cardiology Journal</i> , 2020, 27, 533-540.	0.5	18
10	Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. <i>Atherosclerosis</i> , 2019, 285, 135-146.	0.4	227
11	Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 824-835.	0.8	558
12	Serum uric acid levels are associated with cardiovascular risk score: A post hoc analysis of the EURIKA study. <i>International Journal of Cardiology</i> , 2018, 253, 167-173.	0.8	47
13	Lifestyle and risk factor management in people at high cardiovascular risk from Bulgaria, Croatia, Poland, Romania and the United Kingdom who participated in both the EUROASPIRE III and IV primary care surveys. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1618-1627.	0.8	19
14	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>European Heart Journal</i> , 2016, 37, 2999-3058.	1.0	2,393
15	EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 636-648.	0.8	772
16	Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology. <i>Atherosclerosis</i> , 2015, 241, 169-175.	0.4	133
17	Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. <i>Cardiovascular Diabetology</i> , 2015, 14, 133.	2.7	101
18	Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. <i>Atherosclerosis</i> , 2014, 232, 346-360.	0.4	419

#	ARTICLE	IF	CITATIONS
19	Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: Findings from the EUROASPIRE III survey. <i>Atherosclerosis</i> , 2013, 231, 300-307.	0.4	66
20	Design and methodology of POWER, an open-label observation of the effect of primary care interventions on total cardiovascular risk in patients with hypertension. <i>Fundamental and Clinical Pharmacology</i> , 2013, 27, 210-215.	1.0	6
21	Do novel biomarkers add to existing scores of total cardiovascular risk?. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 14-17.	0.8	13
22	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). <i>European Heart Journal</i> , 2012, 33, 1635-1701.	1.0	5,247
23	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>European Heart Journal</i> , 2011, 32, 1769-1818.	1.0	2,767
24	Prevention of cardiovascular disease in asymptomatic people. <i>Heart</i> , 2010, 96, 477-482.	1.2	3
25	Efficacy and benefits of lipid-lowering drug therapy. The new European guidelines for cardiovascular disease prevention. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2010, 22, 48-51.	0.4	0
26	EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009, 16, 121-137.	3.1	677
27	New European guidelines for cardiovascular disease prevention in clinical practice. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 138-42.	1.4	12
28	Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. <i>Lancet, The</i> , 2009, 373, 929-940.	6.3	737
29	Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited) Tj ETQq1 1 0.784314 0.81 /Over	0.784314	0.81
30	The SCORE model in the POWER study: an attempt to focus the limited resources for prevention on patients with greatest need. <i>Current Medical Research and Opinion</i> , 2007, 23, S19-S24.	0.9	5
31	Diabetes Mellitus in Middle-aged People Is Associated with Increased Sick Leave: The BELSTRESS Study. <i>International Journal of Occupational and Environmental Health</i> , 2006, 12, 28-34.	1.2	20
32	European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). <i>Atherosclerosis</i> , 2004, 173, 381-91.	0.4	57
33	European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force Of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). <i>Archives Des Maladies Du Cœur Et Des Vaisseaux</i> , 2004, 97, 1019-30.	0.3	14
34	European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). <i>European Heart Journal</i> , 2003, 24, 1601-1610.	1.0	1,588
35	European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003, 10, S1-S10.	3.1	152
36	Towards more personalized low-density lipoprotein-cholesterol lowering strategies in patients with atherosclerotic cardiovascular disease. <i>European Journal of Preventive Cardiology</i> , 0, , .	0.8	0